特許事務所 UK支援室
CONTENTS
CONTACT

特許業務法人
HARAKENZO
WORLD PATENT & TRADEMARK


大阪本部    

〒530-0041
大阪市北区天神橋2丁目北
2番6号  大和南森町ビル
TEL:06-6351-4384(代表)
FAX:06-6351-5664(代表)
E-Mail:

東京本部    

〒105-6121
東京都港区浜松町2-4-1
世界貿易センタービル21 階
TEL:03-3433-5810(代表)
FAX:03-3433-5281(代表)
E-Mail:

広島事務所 

〒730-0032
広島市中区立町2-23
野村不動産広島ビル4 階
TEL:082-545-3680(代表)
FAX:082-243-4130(代表)
E-Mail:


上記トレードマークの背景地図は、1991年当時の特許登録件数を陸地の大きさと形状に擬態化して、地図状に表現したものです。

プライバシーポリシー


UK支援室
UK/知財情報 特許事務所 USA知財情報
室長(特許担当者)
意匠・商標担当者
代表電話
FAX
E-mail
: 新井 孝政
: 八谷 晃典
: 06 - 6351 - 4384
: 06 - 6351 - 5664

英国特許出願においてスイス型クレームは認められなくなる

特許業務法人HARAKENZO WORLD PATENT & TRADEMARK
平成22年06月14日
(文責:新 井)

1、はじめに
 2010年2月19日に、EPOの拡大審判部は、G 0002/08において審決を下しました。この審決において、拡大審判部は、付託されていた第1~第3の質問事項のうち、第3の質問に対する回答を提示し、スイス型のクレームに関し後述の新たなルールを示しました。
EP出願プラクティスにおいて、近い将来、スイス型のクレームの使用が禁止されるという新たなルールが適用されます。具体的には、出願人は、Journal of the EPO において本審決G 0002/08が官報での公表から3ヶ月経過後にファイルされる特許出願においてスイス型のクレームの使用は最早認められなくなります。

2、UKIPOの対応
2010年5月26日、UKIPO (UK Intellectual Property Office)は、不明瞭との理由により、2010年5月26日以降、スイス型の医薬クレームを禁止する旨を表明しました。これは、EPOの審決G2/08(2010年2月19日のEPOの拡大審判部による判決)に従うものであり、今後は、"substance X for use in the treatment of disease Y"タイプの医薬第二用途クレームのみが認められることになります。

以下は、UKIPOの表明の抜粋文です。*1

Patents Act 1977: Second medical use claims
1. This Practice Notice sets out the practice of the Intellectual Property Office on the way in which inventions concerning a specific medical use of a substance or composition ("second medical use") may be claimed, in the light of the recent EPO Enlarged Board of Appeal decision in G 02/08 ABBOTT RESPIRATORY/Dosage regime.

Background
2. Prior to 13 December 2007, inventions relating to a specific medical use of a substance or composition, already used in medicine for a different purpose, could only be protected using the "Swiss-type" claim form of "the use of substance X for the manufacture of a medicament to treat disease Y". On this date the Patents Act 2004 implemented the provisions of the revised European Patent Convention (EPC 2000) relating to medical use claims, and introduced Section 4A(4) to the Patents Act 1977. This allows a simpler and more direct second medical use claim, of the form "substance X for use in the treatment of disease Y".

3. Since then, applicants have been allowed to claim inventions relating to second medical uses using either the new, direct second medical use claim format, the Swiss-type format, or both, pending guidance from the UK courts and/or the EPO Boards of Appeal.

4. On 19 February 2010, the EPO Enlarged Board of Appeal issued its decision on G 02/08 ABBOTT RESPIRATORY/Dosage regime. This decided (amongst other things) that applicants may no longer claim second medical use inventions in the Swiss format.

Allowable forms of second medical use claim
5. Subsequent to the decision of the Enlarged Board in G 02/08, only second medical use claims of the form "substance X for use in the treatment of disease Y" will be allowed. Swiss-type second medical use claims will be objected to as lacking clarity. Specifically, Swiss-type claims are considered to be unclear because, although they define a method of manufacturing a medicament, the invention does not in fact relate to the method of production but instead relates to the intended use of the medicament. As stated in G 02/08, there is no functional relationship between the feature conferring novelty (the intended use) and the claimed manufacturing process. As Section 4A(4) now allows a simpler and clearer form of second medical use claim, there is no longer a reason to allow the more ambiguous Swiss form of claim.

6. In G 02/08, the Enlarged Board held that Swiss-type claims were previously accepted (in G 05/83 EISAI/Second medical indication ) as the only possible means of protecting inventions relating to second medical uses in order to fill a loophole in the provisions of the EPC 1973. The new Article 54(5) (equivalent to Section 4A(4)) fills this loophole by explicitly allowing claims to the further specific use of a known drug, and so the reason for this special, "judge-made" law no longer exists. The recent Court of Appeal decision in Actavis v Merck [2008] RPC 26 reaffirmed the desirability of maintaining conformity with EPO practice as established in Board of Appeal decisions in this field, and so Swiss-type claims to second medical uses will no longer be allowed.

Effect of this change - pre-grant applications
7. With immediate effect, Swiss-type claims will be objected to as lacking clarity. Amendment of a patent application to replace a Swiss-type claim with the new form of second medical use claim will be allowed since regardless of the wording or scope of the claim, the technical disclosure (i.e., a new medical use for a substance or composition) is the same.

8. This objection will be made to both new and pending patent applications. While it is recognised that this is inconsistent with EPO practice following G 02/08, whereby Swiss claims will only be objected to for new applications with a priority date of three months or more after publication of the decision in the Official Journal, there is no clear legal basis for such a transitional provision under UK patent law.

Effect of this change - granted patents
9. There is no change in practice in relation to patents already granted and including Swiss-type claims. A request to make a post-grant amendment to replace Swiss-type claims with the new form of second medical use claim is unlikely to succeed, particularly as the Enlarged Board in G 02/08 suggested that the new form of claim may have a broader scope than Swiss-type claims.


以 上


*1 LINK: http://www.ipo.gov.uk/p-pn-medical

このページのトップへ